62. Insights into drug-resistant tuberculosis from Ghana to Peru
Sunday, 06 December 2015, 12:15-13:15

Chair: Nonqubela BANTUBANI (South Africa)

Track: Drug resistance determination - molecular and phenotypic

PC-1221-06  Discordant rifampicin resistance results on MGIT960 and Xpert® MTB/RIF in the TB Control in Prisons Programme of Azerbaijan
E Gurbanova, K Blondal, F Mirzayev, R Tahirli, Vikt Popova, R Mekhdiyev, A Ismayilov, A Altraja (Azerbaijan, Iceland, Switzerland, Estonia)

PC-1222-06  Feasibility of multidrug-resistant tuberculosis treatment with improved regimens based on drug resistance profiles
Mh Wu, R Jou (Taiwan)

PC-1223-06  First- and second-line Mycobacterium tuberculosis drug resistance at a tertiary hospital chest clinic in Ghana
S Kudzawu, M Omari, A Forson, A Badoo, H Ganu, B C De Jong, J Otu, A Kwara, M Antonio (Ghana, Gambia)

PC-1224-06  Stable anti-tuberculosis drug resistance prevalence in Bamako, Mali, 2006-2014
B Diarra, M Sanogo, B Baya, A Togo, Sady Tounkara, S Dao, B De Jong, S Diallo (Mali, Belgium)

PC-1225-06  From facility to finding drug resistance mutations: drug resistance survey in Nigeria
V Sebastian, I Uko, G Akang, T Abiola, S Ogiri, Denn Onotu, N. Nwokoye, M Zignol (Nigeria, Switzerland)

PC-1226-06  Scaling up of a commercial line probe assay for diagnosis of drug resistance and evaluation against an agar proportion method in Peru
Z Puyen, Jr Acosta Barriga, L Solari (Peru)

PC-1227-06  Evaluation of Mycobacterium tuberculosis resistance levels and cross-resistance to isoniazid and rifampicin with their respective structural analogues
I Rukasha, H Said, S Omar, Aw Dreyer, A Hoosen, N Ismail (South Africa)

PC-1228-06  Routine surveillance for anti-tuberculosis drug resistance in two districts of Botswana, 2012–2014
A Finlay, J Basotli, C Modongo, E Click, J Oeltmann, R Boyd, N Zetola, P Moonan (USA, Botswana)